Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Johnson and Johnson
AstraZeneca
Deloitte
Federal Trade Commission
UBS
Teva
Moodys
Covington

Generated: February 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR POMALYST

« Back to Dashboard

Clinical Trials for Pomalyst

Trial ID Title Status Sponsor Phase Summary
NCT00463385 A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia Completed Celgene Corporation Phase 2 The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).
NCT00537511 A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide Terminated Celgene Corporation Phase 1/Phase 2 The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.
NCT00717522 Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma Terminated Celgene Corporation Phase 2 The purpose of the study is to determine the safety and efficacy of single agent CC-4047 (pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to prior anticancer therapy.
NCT00833833 MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Completed Celgene Corporation Phase 1/Phase 2 The purpose of this study is to determine the maximum tolerated dose and effectiveness of the study drug (CC-4047) Alone Or in Combination With Low-dose Dexamethasone as treatment for patients with relapsed and refractory multiple myeloma
NCT00946270 Pomalidomide for Myelofibrosis Patients Active, not recruiting Celgene Phase 2 The goal of this clinical research study is to learn if CC-4047 (now called pomalidomide) and prednisone can help to control MMM. The safety of this therapy will also be studied.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Pomalyst

Condition Name

Condition Name for Pomalyst
Intervention Trials
Multiple Myeloma 17
Recurrent Plasma Cell Myeloma 5
Refractory Plasma Cell Myeloma 4
Multiple Myeloma in Relapse 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Pomalyst
Intervention Trials
Multiple Myeloma 33
Neoplasms, Plasma Cell 32
Lymphoma 3
Lymphoma, Large B-Cell, Diffuse 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Pomalyst

Trials by Country

Trials by Country for Pomalyst
Location Trials
United States 147
Japan 18
Canada 18
Australia 7
Italy 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Pomalyst
Location Trials
Massachusetts 13
California 12
Minnesota 12
New York 10
Florida 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Pomalyst

Clinical Trial Phase

Clinical Trial Phase for Pomalyst
Clinical Trial Phase Trials
Phase 3 3
Phase 2 21
Phase 1/Phase 2 7
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Pomalyst
Clinical Trial Phase Trials
Recruiting 15
Not yet recruiting 11
Active, not recruiting 8
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Pomalyst

Sponsor Name

Sponsor Name for Pomalyst
Sponsor Trials
Celgene Corporation 11
National Cancer Institute (NCI) 10
Celgene 9
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Pomalyst
Sponsor Trials
Industry 42
Other 39
NIH 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
QuintilesIMS
Boehringer Ingelheim
Accenture
Deloitte
Chinese Patent Office
UBS
Johnson and Johnson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.